Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Neuroone Medical Technologies (NMTC) EBITDA Margin (2020 - 2026)

Neuroone Medical Technologies filings provide 12 years of EBITDA Margin readings, the most recent being 87.86% for Q1 2026.

  • On a quarterly basis, EBITDA Margin rose 10543.0% to 87.86% in Q1 2026 year-over-year; TTM through Mar 2026 was 72.69%, a 4156.0% increase, with the full-year FY2025 number at 46.46%, up 29780.0% from a year prior.
  • EBITDA Margin hit 87.86% in Q1 2026 for Neuroone Medical Technologies, down from 59.02% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 52.26% in Q4 2024 to a low of 8616.29% in Q2 2022.
  • Median EBITDA Margin over the past 5 years was 346.8% (2023), compared with a mean of 1452.06%.
  • Biggest five-year swings in EBITDA Margin: crashed -104696bps in 2022 and later surged 805902bps in 2023.
  • Neuroone Medical Technologies' EBITDA Margin stood at 1557.31% in 2022, then skyrocketed by 78bps to 346.8% in 2023, then surged by 115bps to 52.26% in 2024, then crashed by -213bps to 59.02% in 2025, then crashed by -49bps to 87.86% in 2026.
  • The last three reported values for EBITDA Margin were 87.86% (Q1 2026), 59.02% (Q4 2025), and 50.02% (Q3 2025) per Business Quant data.